SCHEMBL17322836

SCHEMBL17322836

COC(=O)Cn1nc(-c2cccc(OCc3ccccc3)c2C)c2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ KDM4E B2RXH2 2/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MAPT P10636 4/20 0.46
▸ TSHR P16473 2/20 0.45
▸ PTGER1 P34995 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HSD17B10 Q99714 2/20 0.42
▸ F2RL3 Q96RI0 1/20 0.40
▸ HTR3A P46098 1/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ SGMS2 Q8NHU3 2/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15631873 0.92 KDM4E (0.64) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17322841 0.89 LMNA (0.58) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17326650 0.86 KDM4E (0.56) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17322868 0.83 KDM4E (0.66) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17322844 0.81 KMT2A (0.58) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL15631848 0.81 KDM4E (0.69) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL15631845 0.79 KDM4E (0.70) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL15631859 0.79 ALDH1A1 (0.74) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL15631880 0.79 KDM4E (0.70) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17322838 0.78 ALDH1A1 (0.57) LMNASMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738610-B2 Indazole derivatives and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2017-08-22 — — US disclosed
US-9738610-B2 Indazole derivatives and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2017-08-22 — — US disclosed
US-20150353503-A1 INDAZOLE DERIVATIVES AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2015-12-10 — — US disclosed
US-20150353503-A1 INDAZOLE DERIVATIVES AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2015-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353503-A1 INDAZOLE DERIVATIVES AND USES THEREOF CYP11B1, HSP90B1, CYP1B1 LMNA 3513/4885SMN1; SMN2 4794/4885KDM4E 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback